ICU Medical, Inc. (ICUI) 股票分析

公司概述

ICU Medical, Inc. operates globally as a developer, manufacturer, and seller of medical products essential for infusion therapy, vascular access, and vital care applications. The company functions within the Healthcare sector, specifically targeting the Medical Instruments & Supplies industry, where it provides specialized equipment such as Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands, alongside Neutron catheter products. This enterprise maintains a substantial scale with a market capitalization of $3.14 billion and generates annual revenue of $2.23 billion, supported by a workforce of 13,000 employees. The combination of a $3.14 billion market cap and $2.23 billion in revenue indicates that the company holds a significant position within the medical device landscape, commanding a valuation that reflects its established role in critical patient care infrastructure despite recent revenue fluctuations.

财务健康

The company reported a Trailing Twelve Months (TTM) revenue of $2.23 billion with a net income of $732,000 and an EBITDA of $310.08 million, highlighting a substantial gap between gross revenue and bottom-line profit that reveals a heavy cost structure or significant non-operating expenses impacting the final net income. Despite the narrow net income, the business generates robust free cash flow of $394.96 million, which signifies strong operational liquidity and provides the financial flexibility to fund operations, repay obligations, or pursue strategic initiatives without relying on external financing. The company's profitability metrics show a gross margin of 36.8%, an operating margin of 4.8%, and a profit margin of 0.0%, indicating that while the core production efficiency is moderate, the final earnings per dollar of revenue are extremely compressed. On the balance sheet, the firm holds $311.71 million in cash against $1.35 billion in debt, resulting in a debt-to-equity ratio of 63.48%, which characterizes a highly leveraged capital structure rather than a conservative one. Liquidity is supported by a current ratio of 2.39, suggesting the company possesses more than double the current assets necessary to cover its short-term liabilities. Return on Equity stands at 0.0% while Return on Assets is 1.7%, metrics that reveal limited effectiveness in generating returns relative to the shareholders' equity and the total asset base utilized.

估值评估

Valuation multiples for ICU Medical show a Trailing P/E ratio of 4194.33 compared to a Forward P/E of 13.67, a drastic disparity that implies the market is pricing in a massive expected earnings turnaround or is currently discounting the stock due to the negligible current earnings. The price-to-book ratio is 1.46, indicating that the market values the company at a moderate premium over its net asset book value, suggesting some confidence in the intangible assets and future earning potential beyond tangible assets. Alternative valuation metrics include a price-to-sales ratio of 1.41 and an EV/EBITDA of 13.36, which suggest the stock is priced at a reasonable multiple relative to its sales and adjusted earnings before interest, taxes, depreciation, and amortization, offering a different perspective than the distorted earnings multiples. The stock has traded within a 52-week range between a low of $107.00 and a high of $160.29, with the current valuation sitting within this historical band. The beta of 0.85 indicates that the stock's price volatility is lower than the broader market, suggesting it may be less sensitive to general market swings than the average equity.

Growth & Income

Revenue growth over the last year stands at -14.1% while earnings growth is marked as N/A, indicating that the company is currently experiencing a contraction in sales which directly impacts its ability to grow earnings in the near term. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests its cash flow back into the business rather than distributing income to shareholders. This non-dividend policy aligns with the strategy of retaining earnings to address the revenue decline and potentially restructure the high debt load rather than rewarding shareholders with cash returns. Overall, the growth and income profile is currently defined by negative revenue momentum and a lack of dividend support, relying instead on the company's existing cash reserves and operational efficiency to navigate the downturn.